Antibody diversity in IVIG: Therapeutic opportunities for novel immunotherapeutic drugs

Antibody diversity in IVIG: Therapeutic opportunities for novel immunotherapeutic drugs

Significant progress has been made in the elucidation of human antibody repertoires. Furthermore, non-canonical functions of antibodies have been identified that reach beyond classical functions linked to protection from pathogens. Polyclonal immunoglobulin preparations such as IVIG and SCIG represe...

Full description

Bibliographic Details
Main Authors:	Stephan von Gunten, Christoph Schneider, Lejla Imamovic, Guy Gorochov
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-03-01
Series:	Frontiers in Immunology
Subjects:	antibodies intravenous immune globulin (IVIg) subcutaneous immunoglobulin IgA immunotherapy
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1166821/full

Similar Items

Mechanism of increased efficacy of recombinant Fc‐μTP‐L309C compared to IVIg to ameliorate mouse immune thrombocytopenia
by: Bonnie J.B. Lewis, et al.
Published: (2021-11-01)

The therapeutic window of intravenous immunoglobulin (IVIG) and its correlation with clinical outcomes in Kawasaki disease: a systematic review and meta-analysis
by: Zheng Li, et al.
Published: (2023-04-01)

Study on the Treatment of ITP Mice with IVIG Sourced from Distinct Sex-Special Plasma (DSP-IVIG)
by: Wei Zhang, et al.
Published: (2023-11-01)

Injection of intravenous immunoglobulin (IVIg) for the treatment of Coronavirus induced cytokine storm
by: Farahnoosh Farnood, et al.
Published: (2022-12-01)

Intravenous immunoglobulins (IVIG) in severe/critical COVID-19 adult patients
by: Dorota Kwapisz, et al.
Published: (2023-07-01)

Using the K/BxN mouse model of endogenous, chronic, rheumatoid arthritis for the evaluation of potential immunoglobulin-based therapeutic agents, including IVIg and Fc-μTP-L309C, a recombinant IgG1 Fc hexamer
by: Bonnie J. B. Lewis, et al.
Published: (2019-12-01)

Efficacy, Safety and Tolerability of a New 10% Intravenous Immunoglobulin for the Treatment of Primary Immunodeficiencies
by: Elena E. Perez, et al.
Published: (2021-07-01)

Paediatric Acute-onset Neuropsychiatric Syndrome (PANS) and intravenous immunoglobulin (IVIG): comprehensive open-label trial in ten children
by: Parisa Hajjari, et al.
Published: (2022-08-01)

Immunoglobulin replacement therapies in inborn errors of immunity: a review
by: Archan Sil, et al.
Published: (2024-02-01)

Corrigendum: MIS-C Treatment: Is IVIG Always Necessary?
by: Francesco Licciardi, et al.
Published: (2022-02-01)

Efficacy of intravenous immunoglobulin (IVIg) on COVID-19-related neurological disorders over the last 2 years: an up-to-date narrative review
by: Paolo Manganotti, et al.
Published: (2023-04-01)

Comparison of Intravenous Immunoglobulin (IVIG) and Intravenous anti-D for Treatment of Acute Idiopathic Thrombocytopenic Purpura
by: Zahra Farahmandinia, et al.
Published: (2010-10-01)

Comparison of Intravenous Immunoglobulin (IVIG) and Intravenous anti-D for Treatment of Acute Idiopathic Thrombocytopenic Purpura
by: Zahra Farahmandinia, et al.
Published: (2010-12-01)

IVIG – A cure to severe refractory NAP-1 Clostridium difficile colitis? A case of successful treatment of severe infection, which failed standard therapy including fecal microbiota transplants and fidaxomicin
by: Kelley Coffman, et al.
Published: (2017-01-01)

Intravenous Immunoglobulin Protects Against Severe Pandemic Influenza Infection
by: Steven Rockman, et al.
Published: (2017-05-01)

Cost-minimisation analysis of plasma exchange versus IVIg in the treatment of autoimmune neurological conditions
by: Tara Klemencic Kozul, et al.
Published: (2022-07-01)

Hyaluronidase facilitated subcutaneous immunoglobulin in primary immunodeficiency
by: Jolles S
Published: (2013-09-01)

Timing of infections in patients with primary immunodeficiencies treated with intravenous immunoglobulin (IVIg)
by: Parwinder K. Gill, et al.
Published: (2018-08-01)

Decreased Steroid Hormone Receptor NR4A2 Expression in Kawasaki Disease Before IVIG Treatment
by: Ying-Hsien Huang, et al.
Published: (2019-02-01)

Case Report: High-dose steroid and IVIG successful treatment in a case of COVID-19-associated autoimmune encephalitis: a literature review
by: Chi-Hung Liu, et al.
Published: (2023-09-01)

Pregnancy associated anti-TIF1 dermatomyositis responsive to intravenous immunoglobulin
by: Jason Kieffer, MD, et al.
Published: (2024-03-01)

Potential intravenous immunoglobulin-induced optic disc edema
by: Anna K. Britton, et al.
Published: (2022-09-01)

The Natural History of Untreated Primary Hypogammaglobulinemia in Adults: Implications for the Diagnosis and Treatment of Common Variable Immunodeficiency Disorders (CVID)
by: Rohan Ameratunga, et al.
Published: (2019-07-01)

Remarkable benefits of intravenous immunoglobulin (IVIG) in a patient with polymyositis-associated acute interstitial lung disease
by: Soran Peshbahar, et al.
Published: (2020-01-01)

Immunomodulation by IVIg and the role of Fc-gamma receptors: classic mechanisms of action after all?
by: Sietse Quirijn Nagelkerke, et al.
Published: (2015-01-01)

Neuroprotective Effect of Polyvalent Immunoglobulins on Mouse Models of Chemotherapy-Induced Peripheral Neuropathy
by: Mohamad Mroué, et al.
Published: (2024-01-01)

Plasma therapy: a passive resistance against the deadliest
by: Anita Hansda, et al.
Published: (2022-04-01)

Editorial: Transfusions in the neonatal period
by: Merih Cetinkaya, et al.
Published: (2022-07-01)

How Should We Classify Kawasaki Disease?
by: Edoardo Marrani, et al.
Published: (2018-12-01)

Enhanced Pro-apoptotic Effects of Fe(II)-Modified IVIG on Human Neutrophils
by: Stefanie Graeter, et al.
Published: (2020-05-01)

Alpha-Synuclein-Specific Naturally Occurring Antibodies Inhibit Aggregation In Vitro and In Vivo
by: Anne K. Braczynski, et al.
Published: (2022-03-01)

Therapeutic Immunoglobulin Selected For High Antibody Titer to RSV Also Contains High Antibody Titers to Other Respiratory Viruses
by: Jordan eOrange
Published: (2015-08-01)

Immunoglobulin utilization in Canada: a comparative analysis of provincial guidelines and a scoping review of the literature
by: Megan Harmon, et al.
Published: (2023-09-01)

Comparing the Outcomes of IVIg with Combination of IVIg and Methylprednisolone in Children with Acute Idiopathic Thrombocytopenia; a Bayesian Logistic Approach
by: Seyed Kamal Eshagh-Hoseini, et al.
Published: (2016-07-01)

Successful Treatment of Scleromyxedema with IVIG: A Case Report
by: Fatemeh Niksolat, et al.
Published: (2018-05-01)

Tonsillectomy Improved Therapeutic Response in Anti-SRP Myopathy With Chronic Tonsillitis
by: Takuya Ikeda, et al.
Published: (2020-11-01)

Therapeutic Potential of HLA-I Polyreactive mAbs Mimicking the HLA-I Polyreactivity and Immunoregulatory Functions of IVIg
by: Mepur H. Ravindranath, et al.
Published: (2021-06-01)

Predictive value of albumin for intravenous immunoglobulin resistance in a large cohort of Kawasaki disease patients
by: Rui Zhang, et al.
Published: (2023-06-01)

Factors predicting poor outcome in patients with fulminant Guillaine-Barré syndrome
by: Nandagopal Nithyashree, et al.
Published: (2014-01-01)

Engineering of Fc Multimers as a Protein Therapy for Autoimmune Disease
by: Elizabeth A. Fitzpatrick, et al.
Published: (2020-03-01)